Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ114411480,26
KB10821087-0,18
PKN63,5863,81-0,25
Msft-1,03
Nokia4,4314,589-0,31
IBM0,10
Mercedes-Benz Group AG50,1750,19-0,32
PFE0,45
18.04.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 17.04.2025
Alnylam Pharm (ALNY.O, NASDAQ Cons)
Závěr k 17.4.2025 Změna (%) Změna (USD) Objem obchodů (ks)
234,56 1,76 4,06 601 350
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 18.04.2025
Popis společnosti
Obecné informace
Název společnostiAlnylam Pharmaceuticals, Inc.
TickerALNY
Kmenové akcie:Ordinary Shares
RICALNY.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.12.2024
Počet zaměstnanců k 31.12.2024 2 230
Akcie v oběhu k 10.03.2025 130 084 858
MěnaUSD
Kontaktní informace
Ulice675 W Kendall St
MěstoCAMBRIDGE
PSČ02142-1168
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 175 518 200
Fax16175518101

Business Summary: Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Alnylam Pharmaceuticals, Inc. revenues increased 23% to $2.25B. Net loss decreased 37% to $278.2M. Revenues reflect AMVUTTRA segment increase of 74% to $970.5M, Regeneron Pharmaceuticals segment increase from $100.5M to $302.8M, United States segment increase of 35% to $933.5M, Europe segment increase of 29% to $516.3M. Lower net loss reflects Interest income increase of 28% to $122M (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 18.04.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, DirectorYvonne Greenstreet6201.01.202219.09.2016
Chief Financial Officer, Executive Vice PresidentJeffrey Poulton5713.08.201913.08.2019
Executive Vice President, Chief Scientific Officer, Head - Early Research and Early DevelopmentKevin Fitzgerald5729.05.2019
Executive Vice President, Chief Legal Officer, SecretaryRobert Hesslein71
Chief Medical Officer, Executive Vice President - Development and Medical AffairsPushkal Garg57
Chief Compliance Officer, DirectorMichael Bonney6605.01.202302.08.2021
Chief Commercial OfficerTolga Tanguler52